In this study, we investigated the efficacy and safety of administration of Linezolid (LZD) to pediatric febrile neutropenia (FN) patients after cancer chemotherapy. The study period was from January 2008 to June 2014, and the subjects were patients under the age of 16 receiving LZD administration (9 subjects, 16 cases, average age 9.2 ∓ 4.4 years). The dose of LZD was 30.7 ∓ 3.1 mg/kg/day, and the administration period was 12.1 ∓ 6.3 days. The test values were as follows: the CRP decreased from 3.9 ∓ 4.5 mg/dL to 0.4 ∓ 0.7 mg/dL (P < 0.01), the PLT increased from 7.1 ∓ 4.69 ⊗ 10 4 /μL to 14.5 ± 9.1 ⊗ 10 4 /μL (P < 0.01) and the WBC increased from 9.4 ± 21.6 ⊗ 10 2 /μL to 42.2 ± 38.5 ⊗ 10 2 /μL (P < 0.01); thus, statistically significant differences were obtained. The reason for the termination of LZD administration was due to the alleviation of the symptoms, which was observed in 14 cases (14/16 87.5％). Survival after 30 days was confirmed in all of the cases. The results suggest that LZD administration to FN pediatric patients is effective and safe.
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